ZYDUS LIFESCIENCES:

CO. LAUNCHES WORLD'S FIRST BIOSIMILAR OF NIVOLUMAB, 'TISHTHA™', IN INDIA FOR MULTIPLE CANCERS; PRICED AT ₹28,950 AND ₹13,950, APPROXIMATELY 1/4TH OF REFERENCE DRUG COST; EXPECTED TO BENEFIT OVER 5 LAKH PATIENTS.